Home  /  Resource Library  /  CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis

CAR T-cells vs. bispecific antibodies as third- or later-line treatment for relapsed/refractory follicular lymphoma: a literature review and meta-analysis

Systematic review comparing bispecific antibodies with CAR-T therapy for treatment of relapsed follicular lymphoma.